Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2

Status

Unknown 2Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 6Sarcoma 1

Conditions

Carcinoma, Basal Cell 4Melanoma 2Sarcoma, Kaposi 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × daromun × Clear all
NCT07227350 2026-06-02

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Philogen S.p.A.

Phase 2 Recruiting
180 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT07227870 2026-03-09

L19IL2/TNF in Patients With Basal Cell Carcinoma

Philogen S.p.A.

Phase 2 Not yet recruiting
92 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT06284590 2024-10-26

INTACT/MeRCI

Philogen S.p.A.

Phase 2 Recruiting
162 enrolled
Dermatologic

Melanoma

NCT04362722 2023-10-10

DUNCAN

Philogen S.p.A.

Phase 2 Unknown
40 enrolled
Dermatologic

Carcinoma, Carcinoma, Basal Cell

NCT05329792 2023-10-06

IntriNSiC

Philogen S.p.A.

Phase 2 Unknown
70 enrolled
DermatologicSarcoma

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Sarcoma, Kaposi, Carcinoma, Merkel Cell

NCT02076633 2015-05-27

Intratumoral Administration of L19IL2/L19TNF

Philogen S.p.A.

Phase 2 Completed
21 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡